Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK3.97 0.0  0.0%

Last Trade - 12/05/21

Sector
Industrials
Size
Small Cap
Market Cap £123.0m
Enterprise Value £114.2m
Revenue £2.85m
Position in Universe 846th / 1832

BRIEF-BioPorto Receives Communication From FDA Regarding The NGAL Test

Thu 4th October, 2018 2:21am
Oct 3 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * BIOPORTO RECEIVES COMMUNICATION FROM FDA REGARDING THE
NGAL TEST
    * FDA COMMUNICATION STATES THAT ADDITIONAL DATA WILL BE
REQUIRED
TO SUPPORT AKI RULE-OUT CLAIM IN ORDER TO CONTINUE APPLICATION
PROCESS
    * BIOPORTO WILL NOW ENTER INTO A DIALOGUE WITH FDA TO
FURTHER
CLARIFY THESE ISSUES
    * MANAGEMENT'S EXPECTATION AS TO TIMING OF FDA'S DECISION
REGARDING CLEARANCE OF NGAL TEST IS THEREFORE POSTPONED TO
MID-2019

Source text for Eikon:  ID:nGNE6KJKnw 
Further company coverage:  BIOPOR.CO 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.